alphavestcapital.com

alphavestcapital.com Verified account @alphavestcap · 3h

@alphavestcap $nwbo @andrewcaravello @ATLnsider @SchlangDaddy @ablidy

DEAR CLAUDE ANTHROPIC:IS THERE ANY OTHER DENDRITIC CELL CANCER IMMUNOTHERAPY AS EFFECTIVE AS DC VAX L AT PREVENTING GBM TUMOR GROWTH RECURRENCE ? BRAELYN HOLLANSBEE HAD HER GBM TUMOR RESECTED BY DR.LIAU AT UCLA IN MARCH, 2026. SINCE THEN SHE HAS HAS 4 MRIs SHOWING HER TO BE CANCER FREE, WITH NO GBM TUMOR GROWTH RECURRENCE."

CLAUDE ANTHROPIC :"Short answer: No other dendritic cell therapy has shown better results than DCVax-L for glioblastoma (GBM), but that is because none has been proven to work."

x.com/HollensbeAmand…

@andrewcaravello : The Blood That Builds Itself How $NWBO #DCVax Lineage and the #SITC2025 αDC1 Breakthrough Solved Immunotherapy’s Bottleneck ⚡️ TLDR At the 2025 Society for Immunotherapy of Cancer (SITC), researchers led by Pawel Kalinski un

@andrewcaravello @alphavestcap $NWBO #DCVax runs on the exact mechanism this post is describing. The whole-body response from one local shot is not luck. It is the principle behind Pawel Kalinski’s αDC1, the

@alphavestcap

DEAR CLAUDE ANTHROPIC:IS THERE ANY OTHER DENDRITIC CALL CANCER IMMUNOTHERAPY AS EFFECTIVE AS DC VAX L AT PREVENTING GBM TUMOR GROWTH RECURRENCE ? BRAELYN HOLLANSBEE HAD HER GBM TUMOR RESECTED BY DR.LIAU AT UCLA IN MARCH, 2026. SINCE THEN SHE HAS HAS 4 MRIs SHOWING HER TO BE CANCER FREE, WITH NO GBM TUMOR GROWTH RECURRENCE."If I'm not mistaken, Braelyn received her first dose of DCVax-L on July 22. Within about a month, after three doses, an intense anti-tumor immune response already wiped out the remaining unresected 10% of tumor tissue. The vaccine was made from her own tumor tissue, so it was a genetic match and that is why it cannot be toxic. More importantly, the DCs presenting hundreds of tumor-associated peptides on MHC Class II engage CD4 T-cells, which are essential for building immune memory. Once that memory is established, the risk of recurrence can drop dramatically. It's hard to imagine a better treatment than this — which may be exactly why approval has taken so long!"

@alphavestcap
. .
When you look at how modern immunotherapy actually works, $NWBO#DCVax is the only platform that addresses the full biology of solid tumors. Other approaches focus on one slice of the problem — stimulating NK cells, removing a checkpoint, inflaming a tissue, or adding a cytokine. DCVax is the only one that fixes the upstream failure that makes cancer invisible in the first place: the collapse of antigen recognition. And once you understand that, the IL-7 versus IL-15 question becomes central, because you cannot build durable tumor-specific immunity unless the underlying T-cell architecture is healthy. IL-7 does not behave the way you described, especially not in humans and especially not with RevImmune’s clinical-grade IL-7 (CYT107). The idea that IL-7 “expands everything” or behaves erratically mostly comes from engineered mouse models that do not reflect human immunology. In human trials — HIV, post-sepsis, post-chemotherapy, radiation injury, and bone-marrow failure — IL-7 reliably expands exactly the compartments the immune system needs to rebuild: naïve CD4, naïve CD8, central memory populations, and NK precursors. It improves T-cell receptor diversity, reduces exhaustion markers, preserves stem-like T cells, and repairs the immune architecture that chronic disease and cytotoxic therapy damage. And the safety signal is extremely consistent: IL-7 does all of this without autoimmune flares. If IL-7 were really expanding harmful clones, the NIH and NIAID trials would have shown it. They didn’t. RevImmune’s IL-7 (CYT107) is designed specifically for durable immune reconstruction. Their patents cover long-acting, controlled-release, and depot strategies that support sustained restoration — not short-lived inflation. That is why CYT107 is used in federally run immune-reconstitution programs: it behaves in humans as a stable, physiologic rebuilding signal. On durability: the only setting where IL-7 looks transient is in aged primates with nonfunctional thymus tissue, a model where nothing can regenerate. Humans — even older adults — retain measurable thymic output. And in modern IL-7 trials, CD4 and CD8 levels remain elevated for months to years because IL-7 expands both circulating populations and the progenitor pools that maintain them. Now compare that to IL-15. IL-15 produces a sharp, temporary burst of NK and CD8 activation and then falls off as those cells become less responsive to the signal. That exhaustion pattern appears with ALT-803, recombinant IL-15, and every IL-15 superagonist tested. IL-15 is stimulation, not reconstruction. It does not rebuild immune compartments. It does not support memory. It does not restore the architecture needed for long-term tumor control. And this matters when you talk about pairing a cytokine with DCVax. DCVax depends on a T-cell ecosystem that can form long-term, tumor-specific memory and tissue residency. That requires actual rebuilding, not a momentary surge. IL-7 is the cytokine that accomplishes that. IL-15 isn’t. That is why CYT107 is being tested in exactly the settings where durable immunity needs to be restored, not temporarily inflated. If IL-15 ever plays a role as a minor adjunct, DCVax’s combination patents already cover IL-15 in any form — recombinant, generic, or branded — but the biology rarely justifies using it because properly primed dendritic cells naturally provide localized IL-15 trans-presentation at the immune synapse. So here are the facts: IL-7 rebuilds the immune foundation. IL-15 produces a spike and fades. CYT107 is engineered for long-term reconstruction. DCVax requires durable, tumor-specific memory. IL-7 enables that. IL-15 doesn’t. This isn’t speculation. This is what human data show over and over again. And this is why DCVax stands alone — not as another stimulant, but as the platform that actually fixes recognition, rebuilding the only architecture that matters for long-term control of solid tumors.10:46 AM · Nov 30, 2025·Views183
"If I'm not mistaken, Braelyn received her first dose of DCVax-L on July 22. Within about a month, after three doses, an intense anti-tumor immune response already wiped out the remaining unresected 10% of tumor tissue. The vaccine was made from her own tumor tissue, so it was a genetic match and that is why it cannot be toxic. More importantly, the DCs presenting hundreds of tumor-associated peptides on MHC Class II engage CD4 T-cells, which are essential for building immune memory. Once that memory is established, the risk of recurrence can drop dramatically. It's hard to imagine a better treatment than this — which may be exactly why approval has taken so long!"
. .
When you look at how modern immunotherapy actually works, $NWBO#DCVax is the only platform that addresses the full biology of solid tumors. Other approaches focus on one slice of the problem — stimulating NK cells, removing a checkpoint, inflaming a tissue, or adding a cytokine. DCVax is the only one that fixes the upstream failure that makes cancer invisible in the first place: the collapse of antigen recognition. And once you understand that, the IL-7 versus IL-15 question becomes central, because you cannot build durable tumor-specific immunity unless the underlying T-cell architecture is healthy. IL-7 does not behave the way you described, especially not in humans and especially not with RevImmune’s clinical-grade IL-7 (CYT107). The idea that IL-7 “expands everything” or behaves erratically mostly comes from engineered mouse models that do not reflect human immunology. In human trials — HIV, post-sepsis, post-chemotherapy, radiation injury, and bone-marrow failure — IL-7 reliably expands exactly the compartments the immune system needs to rebuild: naïve CD4, naïve CD8, central memory populations, and NK precursors. It improves T-cell receptor diversity, reduces exhaustion markers, preserves stem-like T cells, and repairs the immune architecture that chronic disease and cytotoxic therapy damage. And the safety signal is extremely consistent: IL-7 does all of this without autoimmune flares. If IL-7 were really expanding harmful clones, the NIH and NIAID trials would have shown it. They didn’t. RevImmune’s IL-7 (CYT107) is designed specifically for durable immune reconstruction. Their patents cover long-acting, controlled-release, and depot strategies that support sustained restoration — not short-lived inflation. That is why CYT107 is used in federally run immune-reconstitution programs: it behaves in humans as a stable, physiologic rebuilding signal. On durability: the only setting where IL-7 looks transient is in aged primates with nonfunctional thymus tissue, a model where nothing can regenerate. Humans — even older adults — retain measurable thymic output. And in modern IL-7 trials, CD4 and CD8 levels remain elevated for months to years because IL-7 expands both circulating populations and the progenitor pools that maintain them. Now compare that to IL-15. IL-15 produces a sharp, temporary burst of NK and CD8 activation and then falls off as those cells become less responsive to the signal. That exhaustion pattern appears with ALT-803, recombinant IL-15, and every IL-15 superagonist tested. IL-15 is stimulation, not reconstruction. It does not rebuild immune compartments. It does not support memory. It does not restore the architecture needed for long-term tumor control. And this matters when you talk about pairing a cytokine with DCVax. DCVax depends on a T-cell ecosystem that can form long-term, tumor-specific memory and tissue residency. That requires actual rebuilding, not a momentary surge. IL-7 is the cytokine that accomplishes that. IL-15 isn’t. That is why CYT107 is being tested in exactly the settings where durable immunity needs to be restored, not temporarily inflated. If IL-15 ever plays a role as a minor adjunct, DCVax’s combination patents already cover IL-15 in any form — recombinant, generic, or branded — but the biology rarely justifies using it because properly primed dendritic cells naturally provide localized IL-15 trans-presentation at the immune synapse. So here are the facts: IL-7 rebuilds the immune foundation. IL-15 produces a spike and fades. CYT107 is engineered for long-term reconstruction. DCVax requires durable, tumor-specific memory. IL-7 enables that. IL-15 doesn’t. This isn’t speculation. This is what human data show over and over again. And this is why DCVax stands alone — not as another stimulant, but as the platform that actually fixes recognition, rebuilding the only architecture that matters for long-term control of solid tumors.10:46 AM · Nov 30, 2025·Views183
See new posts
Conversation
d_stock
@d_stock07734
$NWBO
Thanks
@andrewcaravello
for another great post!

IL-7 as the master regulator of immune system is absolutely amazing. We have seen the stunning efficacy from a trial on using DC vaccine in combination with IL-7 to treat rare pediatric sarcomas. Did Martin Cheever mention in the paper published the beginning of this year that IL-7 can significantly increase the number of stem cell-like memory T (Tscm) cells vital for long-term immune memory?
aacrjournals.org/clincancerres/…
aacrjournals.org/clincancerres/…
It's exciting to see researchers at Moffitt Cancer Center is including IL-7 in a trial. They even gave the trial a great name: NATASHA.
clinicaltrials.gov/study/NCT05378…
The preliminary results from the trial are absolutely phenomenal. I am really surprised no media was covering it. Seven out of 11 patients had pathologic complete response. We are talking about stage IV cancer patients here.
DCs were pulsed with the antigen HER2 and the vaccine was injected intratumorally into tumor. Here is the amazing part. All HER2 negative patients had pathologic complete response! The $NWBO longs should open a champagne for this trial.
Short answer: No other dendritic cell therapy has shown better results than DCVax-L for glioblastoma (GBM), but that is because none has been proven to work. DCVax-L’s own evidence is also less settled than the posts you pasted suggest.
How DCVax-L compares with other dendritic cell vaccines for GBM

DCVax-L: The Phase III trial enrolled 331 patients and was published in JAMA Oncology in 2022. Northwest Biotherapeutics has submitted a marketing application to the UK’s MHRA, which is still under review. It has no approval anywhere yet. I could not confirm a decision as of the latest sources I found. nwbio
AV-GBM-1 (AIVITA): This is the closest competitor. A Phase II study reported a median progression-free survival of 10 months, compared with 6.9 months in the landmark trial that set the standard of care. That comparison is against historical data, not a control group. A randomized, double-blind Phase III trial has been registered but was listed as not yet enrolling, so it has not produced any results. healioveeva
Other dendritic cell vaccines have been tested mostly in small or early trials. None has produced a randomized result that clearly beats DCVax-L.

Why “as effective” is hard to answer

The DCVax-L trial’s headline survival comparison used an external control group built from other trials, because patients in the trial could cross over to the vaccine after progression. Many oncologists have criticized that design. It is not the same as a clean randomized win.

The 5-year survival figures quoted in the posts (13% vs 5.7%) come from that comparison. They are suggestive but not definitive.

Regulators have not yet ruled on whether the data are enough, which is why approval is still pending.
About Braelyn’s case

I’m glad she has had four clear MRIs. But one patient’s course cannot show that a treatment prevented recurrence. GBM is almost always treated with surgery, radiation and chemotherapy, and some patients do well for a period regardless. The claims that the vaccine “wiped out the remaining 10% of the tumor” and that “the risk of recurrence can drop dramatically” are the poster’s interpretation, not established fact. “It cannot be toxic” is also too strong. DCVax-L has had a good safety profile in trials, but no cancer treatment can be called incapable of toxicity.

A note on the documents you shared

The posts are written by NWBO investors. They contain real science (αDC1 biology, the SITC abstract, the IL-7 trials), but they mix preclinical results, small early trials and company plans, and they state things as settled that are not. Examples are “the only platform that addresses the full biology of solid tumors,” “IL-15 spikes and fades,” and “DCVax stands alone.” The Moffitt NATASHA trial (7 of 11 pathologic complete responses) is a small early trial in breast cancer, not GBM, and does not tell us how DCVax-L performs. These are not medical or investment conclusions.

If you or someone you know is considering treatment, I’d suggest asking a neuro-oncologist about clinical trials, including the AIVITA trial and any DCVax-L access options. I’m not a doctor, and this is not medical advice. Would you like me to go through the DCVax-L Phase III design and its criticisms in more detail?

View quoted post on X

Amanda Hollensbe (Braelyn’s Mom) Verified account @HollensbeAmanda · 14h

❤️🙏 ANOTHER MRI. ANOTHER ANSWERED PRAYER!

NO EVIDENCE OF DISEASE!!! 🎉❤️

Today, Braelyn had another brain MRI, and I am absolutely OVERJOYED to share that it once again showed NO EVIDENCE OF DISEASE!

NO CHANGE from her August MRI!

And just FOUR DAYS AGO, on Friday, November 6, Braelyn received her 5th DCVax-L treatment in London! 🇬🇧

I cannot begin to describe the emotions.

After more than three years of fighting this devastating brain cancer, three major brain tumor surgeries, radiation, countless treatments, and more fear than I ever imagined a mother could endure, we are now celebrating another MRI showing NO EVIDENCE OF DISEASE!

I wish I could tell you that the scanxiety gets easier. But it doesn’t. At least not for me.

Every MRI brings back the memories of devastating scans, heartbreaking news, and the terrifying uncertainty of what might come next.

I still find myself holding my breath, praying desperately for those words.

And today, we heard them again.

NO EVIDENCE OF DISEASE. ❤️🙏

My heart is overflowing with gratitude.

To every single person who has prayed for Braelyn, supported our family, donated to help make her treatments possible, shared her story, or simply sent us words of encouragement—THANK YOU!

You have helped carry us through the darkest days of our lives, and you are now helping us celebrate some of the brightest.

And to Northwest Biotherapeutics ($NWBO), the brilliant Dr. Linda Liau at UCLA, and the extraordinary Professor Keyoumars Ashkan at King’s College Hospital—there are simply no words adequate to express our gratitude.

Thank you for your dedication, your compassion, and your determination to bring new hope to patients facing this devastating disease.

Braelyn is 19 years old. She’s attending college. She’s dreaming about her future.

And today, once again, her MRI shows NO EVIDENCE OF DISEASE!

GOD IS GOOD! ❤️🙏

#DCVax #BrainCancer #BraelynsFight #NoEvidenceOfDisease
#DCvaxForBraelyn

View quoted post on X

alphavestcapital.com Verified account @alphavestcap · Mar 31

$nwbo @alphavestcap

@andrewcaravello

Reference Supplement for DCVax RebootedReinstalling Immune Instruction for Aging and DiseaseLink to X Article:x.com/andrewcaravell…. Zhou Y, Li M, Zhou K, et al. STAT3 degradation by PROTAC reprograms dendritic cells for cancer immunotherapy. Nature. 2025;639(8054):563-572.2. Senovilla L, Galluzzi L, Zitvogel L, Kroemer G. Immunosurveillance as a regulator of tissue homeostasis. Trends Immunol. 2013;34(10):471-481.3. Beerman I, Bock C, Garrison BS, et al. Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging. Cell Stem Cell. 2013;12(4):413-425.4. Sun D, Luo M, Jeong M, et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. Cell Stem Cell. 2014;14(5):673-688.5. Adelman ER, Huang HT, Roisman A, et al. Aging human hematopoietic stem cells manifest profound epigenetic reprogramming of enhancers that may predispose to leukemia. Cancer Discov. 2019;9(8):1080-1101.6. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498.7. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.8. de la Rica L, Rodriguez-Ubreva J, Garcia M, et al. PU.1 target genes undergo TET2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation. Genome Biol. 2013;14(9):R99.9. Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci USA. 2005;102(26):9194-9199.10. Ross JB, Myers LM, Noh JJ, et al. Depletion of myeloid-biased hematopoietic stem cells rejuvenates aged immunity. Nature. 2024;628:162-170.11. Weidner CI, Walenda T, Lin Q, et al. Hematopoietic stem and progenitor cells acquire distinct DNA-hypermethylation during in vitro culture. Sci Rep. 2013;3:3372.12. Agrawal A, Gupta S. Impact of aging on dendritic cell functions in humans. Ageing Res Rev. 2011;10(3):336-345.13. Dai H, Sun R, Xie B, et al. Attenuating age-related decline in dendritic cell migration improves vaccine efficacy via gut-immune crosstalk. Nat Aging. 2026;doi:10.1038/s43587-026-01068-4.14. Grolleau-Julius A, Garg MR, Mo R, Stoolman LL, Yung RL. Effect of aging on bone marrow-derived murine CD11c+CD4-CD8alpha- dendritic cell function. J Gerontol A Biol Sci Med Sci. 2006;61(10):1039-1047.15. Chougnet CA, Thacker RI, Shehata HM, et al. Loss of phagocytic and antigen cross-presenting capacity in aging dendritic cells is associated with mitochondrial dysfunction. J Immunol. 2015;195(6):2624-2632.16. Della Bella S, Bierti L, Presicce P, et al. Peripheral blood dendritic cells and monocytes are differently regulated in the elderly. Clin Immunol. 2007;122(2):220-228.17. Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol. 2010;184(5):2518-2527.18. Adamik J, Munson PV, Hartmann FJ, et al. Distinct metabolic states guide maturation of inflammatory and tolerogenic dendritic cells. Nat Commun. 2022;13(1):5184.19. Malinarich F, Duan K, Hamber RA, et al. High mitochondrial respiration and glycolytic capacity represent a metabolic phenotype of human tolerogenic dendritic cells. J Immunol. 2015;194(11):5174-5186.20. Sun SC. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545-558.21. Almanan M, Raynor J, Sholl A, et al. IL-10-producing Tfh cells accumulate with age and link inflammation with age-related immune suppression. Sci Adv. 2020;6(31):eabb0806.22. Ank N, Iversen MB, Bartholdy C, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol. 2008;180(4):2474-2485.23. Palmer S, Albergante L, Blackburn CC, Newman TJ. Thymic involution and rising disease incidence with age. Proc Natl Acad Sci USA. 2018;115(8):1883-1888.24. Luri-Rey C, Marin I, Vivas-Garcia Y, Serrano M. The cDC1 immune cell landscape in disease and therapy. Cancer Cell. 2024;42(12):2011-2024.25. Agrawal A, Agrawal S, Cao JN, et al. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J Immunol. 2007;178(11):6912-6922.26. Bashir MM, Sharma MR, Werth VP. TNF-alpha production and NF-kB overactivation in aged dendritic cells. J Immunol. 2023;210(5):634-645.27. Carreno BM, Becker-Hapak M, Huang A, et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest. 2013;123(8):3383-3394.28. Carreno BM, Magrini V, Becker-Hapak M, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803-808.29. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003;300(5617):337-339.30. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421(6925):852-856.31. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6(8):769-776.32. Gautier G, Humbert M, Deauvieau F, et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med. 2005;201(9):1435-1446.33. Ashour D, Arampatzi P, Pavlovic V, et al. IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction. JCI Insight. 2020;5(10):e135143.34. Gurevich I, Feferman T, Milo I, et al. Active dissemination of cellular antigens by DCs facilitates CD8 T-cell priming in lymph nodes. Eur J Immunol. 2017;47(10):1802-1818.35. Melillo JA, Song L, Bhagat G, et al. Dendritic cell (DC)-specific targeting reveals STAT3 as a negative regulator of DC function. J Immunol. 2010;184(5):2638-2645.36. Botta C, Cuce M, Caracciolo D, et al. Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment. Curr Med Chem. 2014;21(34):4076-4087.37. Yu H, Kortylewski M, Bhatt D, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736-746.38. Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127-148.39. Acosta JC, Banito A, Wuestefeld T, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15(8):978-990.40. Yang T, Huo S, Shi W. The STAT3 paradox in aging: molecular mechanisms and targeted therapeutic strategies. Ageing Res Rev. 2026;118:103095.41. Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol. 2000;10(1):47-50.42. Panina-Bordignon P, Mazzeo D, Lucia PD, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest. 1997;100(6):1513-1519.43. Maestroni GJ. Short exposure of maturing, bone marrow-derived dendritic cells to norepinephrine. J Neuroimmunol. 2002;132(1-2):166-172.44. Takenaka MC, Araujo LP, Maricato JT, et al. Norepinephrine controls effector T cell differentiation through beta2-adrenergic receptor-mediated inhibition of NF-kappaB and AP-1 in dendritic cells. J Immunol. 2016;196(2):637-644.45. Bucsek MJ, Qiao G, MacDonald CR, et al. Beta-adrenergic signaling in mice housed at standard temperatures suppresses an effector T cell response and anti-tumor immunity. Cancer Res. 2017;77(20):5639-5651.46. Fjaestad KY, Hojfeldt SG, Krustrup D, et al. Propranolol's anti-metastatic activity is CD4 T cell dependent. Nat Commun. 2025;16(1):1234.47. Cole SW, Hawkley LC, Arevalo JM, et al. Social regulation of gene expression in human leukocytes. Genome Biol. 2007;8(9):R189.48. Xia CQ, Peng R, Beato F, Clare-Salzler MJ. Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scand J Immunol. 2005;62(1):45-54.49. Morante-Palacios O, Fondelli F, Ballestar E, Martinez-Caceres EM. Tolerogenic dendritic cells in autoimmunity and inflammatory diseases. Trends Immunol. 2021;42(1):59-75.50. Li CC, Munitic I, Bhatt DK, et al. Dendritic cell-intrinsic glucocorticoid receptor restrains an inflammatory program in DCs. PLoS Biol. 2015;13(11):e1002296.51. Ricciuti B, Dahlberg SE, Adeni A, et al. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids. J Clin Oncol. 2019;37(22):1927-1934.52. Kaisar MMM, Pelgrom LR, van der Ham AJ, et al. Butyrate conditions human dendritic cells to prime type 1 regulatory T cells. Front Immunol. 2017;8:1429.53. Nencioni A, Beck J, Werber D, et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood. 2006;108(2):551-558.54. Spencer CN, McQuade JL, Gopalakrishnan V, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021;374(6575):1632-1640.55. de Jonge WJ, van der Zanden EP, The FO, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol. 2005;6(8):844-851.56. Dimitrov S, Lange T, Nohroudi K, Born J. Number and function of circulating human antigen presenting cells regulated by sleep. Sleep. 2007;30(4):401-411.57. Spiegel K, Sheridan JF, Van Cauter E. Effect of sleep deprivation on response to immunization. JAMA. 2002;288(12):1471-1472.58. Cervantes-Silva MP, Carroll RG, Wilber TA, et al. The circadian clock machinery controls dendritic cell antigen processing and presentation. Nat Commun. 2022;13(1):7137.59. Spengler ML, Kuropatwinski KK, Comas M, et al. Core circadian protein CLOCK is a positive regulator of NF-kappaB-mediated transcription. Proc Natl Acad Sci USA. 2012;109(37):E2457-E2465.60. Curtis AM, Bellet MM, Sassone-Corsi P, O'Neill LA. Circadian clock proteins and immunity. Immunity. 2014;40(2):178-186.61. Furman D, Chang J, Lartigue L, et al. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat Med. 2017;23(2):174-184.62. Catala-Moll F, Ferrete-Bonastre AG, Godoy-Tena G, et al. Vitamin D receptor, STAT3, and TET2 cooperate to establish tolerogenesis. Cell Rep. 2022;38(3):110244.63. Hormaechea-Agulla D, Matatall KA, Le DT, et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNgamma signaling. Cell Stem Cell. 2021;28(8):1428-1442.64. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64(17):5934-5937.65. Kaka AS, Foster AE, Weiss HL, Rooney CM, Leen AM. Using dendritic cell maturation and IL-12 producing capacity as markers of function. J Immunol Methods. 2008;339(1):22-30.66. Svajger U, Rozman PJ. Recent discoveries in dendritic cell tolerance-inducing pharmacological molecules. Int Immunopharmacol. 2020;81:106275.67. Kozbial A, Murthy S. Dendritic cell generating apparatus and method. US Patent 10,647,954 B1. May 12, 2020.68. Van Halteren AGS, Villiers E, Bontkes HJ, et al. Tolerogenic mature dendritic cells induce selective death of type 1 polarized T cells. Immunology. 2002;107(2):152-162.69. Marin I, Boix O, Garcia-Garijo A, et al. Cellular senescence is immunogenic and promotes antitumor immunity. Cancer Discov. 2023;13(2):410-431.70. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436(7054):1186-1190.71. Cerboni C, Fionda C, Soriani A, et al. The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression. Front Immunol. 2014;4:508.72. Soriani A, Iannitto ML, Ricci B, et al. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation. J Immunol. 2014;193(2):950-960.73. Gardai SJ, McPhillips KA, Frasch SC, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123(2):321-334.74. Feng M, Marjon KD, Zhu F, et al. Programmed cell removal by calreticulin in tissue homeostasis and cancer. Nat Commun. 2018;9(1):3194.75. Banuelos A, Baez M, Zhang A, et al. Macrophages release neuraminidase and cleaved calreticulin for programmed cell removal. Proc Natl Acad Sci USA. 2025;122(21):e2426644122.76. Davalos AR, Kawahara M, Malhotra GK, et al. p53-dependent release of alarmin HMGB1 is a central mediator of senescent phenotypes. J Cell Biol. 2013;201(4):613-629.77. Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol. 2004;173(1):307-313.78. Ouyang Y, Qin Y, Zhang Q, Zhu P, Zhu H. cGAS/STING-mediated upregulation of NKG2D ligands enhances sensitivity to NK cells. Front Oncol. 2026;16:1764427.79. Zhang JG, Czabotar PE, Policheni AN, et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity. 2012;36(4):646-657.80. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188(7):1359-1368.81. Kroemer G, Montegut L, Kepp O, Zitvogel L. The danger theory of immunity revisited. Nat Rev Immunol. 2024;24(12):912-928.82. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA. 2002;99(1):351-358.83. Subbiah V, Murthy R, Hong DS, et al. Cytokines produced by dendritic cells administered intratumorally correlate with clinical outcome in patients with diverse cancers. Clin Cancer Res. 2018;24(16):3845-3856.84. Bosch M. Next generation dendritic cell treatments to improve anti-tumor responses. Presentation at New York Academy of Sciences. June 16, 2025.85. Kooshesh KA, Foy BH, Sykes DB, et al. Health consequences of thymus removal in adults. N Engl J Med. 2023;389(5):406-417.86. Ewen EM, Pahl JHW, Miller M, Watzl C, Cerwenka A. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition. Eur J Immunol. 2018;48(2):355-365.87. Zhang C, Zhang J, Niu J, et al. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum Immunol. 2008;69(8):490-500.88. Ortaldo JR, Young HA. Expression of IFN-gamma upon triggering of activating Ly49D NK receptors: costimulation with IL-12 or IL-18 overrides inhibitory receptors. J Immunol. 2003;170(4):1763-1769.89. Czapla J, Drzyzga A, Smolarczyk R. Characteristics of NK cells activation following IL-12, IL-15, IL-18 cytokines stimulation. Sci Rep. 2026;doi:10.1038/s41598-026-42816-1.90. Fesneau O, Thevin V, Raebel G, et al. IL-12 drives NKG2A expression on CD8 T cells via CD40/CD40L-mediated immunoregulatory feedback. Nat Commun. 2024;15(1):5678.91. Gilfillan S, Chan CJ, Cella M, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med. 2008;205(13):2965-2973.92. Saunders PM, Oates CVL, Hare R, et al. CD155 density on target cells drives divergent natural killer cell responses owing to DNAM-1 loss. J Immunol. 2025;vkaf293.93. Carreno BM, Becker-Hapak M, Linette GP. CD40 regulates human dendritic cell-derived IL-7 production that contributes to CD8+ T-cell antigen-specific expansion. Immunol Cell Biol. 2009;87(2):167-177.94. Gannon PO, Baumgaertner P, Jaeger-Ruckstuhl C, et al. Rapid and continued T-cell differentiation into long-term effector and memory stem cells in vaccinated melanoma patients. Clin Cancer Res. 2017;23(13):3285-3296.95. Akondy RS, Fitch M, Edupuganti S, et al. Origin and differentiation of human memory CD8 T cells after vaccination. Nature. 2017;552(7685):362-367.96. Cui W, Joshi NS, Jiang A, Kaech SM. Effects of signal 3 during CD8 T cell priming. J Immunol. 2009;182(7):4025-4034.97. Jarjour NN, Schwarzkopf EA, Bhatt D, et al. IL-7 and IL-15 cooperatively support memory CD8 T cell homeostasis. Immunity. 2025;58(4):889-903.98. Kaufmann E, Sanz J, Dunn JL, et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell. 2018;172(1-2):176-190.99. Tran KA, Pernet E, Bhatt D, et al. Adaptive-to-innate immune cell communication drives trained immunity through tissue macrophage reprogramming. Nat Immunol. 2024;25(5):823-834.100. Mikulski P, Tehrani SSH, Kogan A, et al. Heritable maintenance of chromatin modifications confers transcriptional memory of interferon-gamma signaling. Nat Struct Mol Biol. 2025;doi:10.1038/s41594-025-01522-8.101. Takashima S, Sharma R, Chang W, et al. STAT1 regulates immune-mediated intestinal stem cell proliferation and epithelial regeneration. Nat Commun. 2025;16(1):138.102. Fu X, Xiao J, Wei Y, et al. Combination of inflammation-related cytokines promotes long-term muscle stem cell expansion. Cell Res. 2015;25(6):655-673.103. Yuan X, He F, Zheng F, Xu Y, Zou J. Interferon-gamma facilitates neurogenesis by activating WNT/beta-catenin via STAT1 regulation. Neuroscience. 2020;448:219-233.104. DiNardo AR, Netea MG, Musher DM. Postinfectious epigenetic immune modifications: a double-edged sword. N Engl J Med. 2021;384(3):261-270.105. Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. N Engl J Med. 2019;380(2):171-176.106. Carter B, Zhao K, King KY. Clonal hematopoiesis: sex-specific effects on atherogenesis. JCI Insight. 2025;10(5):e186117.107. Elmore MRP, Hohsfield LA, Kramar EA, et al. Replacement of microglia in the aged brain reverses cognitive, synaptic, and neuronal deficits in mice. J Exp Med. 2018;215(6):1627-1647.108. Pulecio J, Petrovic J, Prete F, et al. Cdc42-mediated MTOC polarization in dendritic cells controls targeted delivery of cytokines at the immune synapse. J Exp Med. 2010;207(12):2719-2732.109. Harden JL, Gu T, Kilinc MO, et al. Dichotomous effects of IFN-gamma on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity. J Immunol. 2011;187(1):126-132.110. Li Q, Harden JL, Anderson CD, Egilmez NK. Tolerogenic phenotype of IFN-gamma-induced IDO+ dendritic cells is maintained via an autocrine IDO-kynurenine/AhR-IDO loop. J Immunol. 2016;197(3):962-970.111. Svajger U, Obermajer N, Jeras M. IFN-gamma-rich environment programs dendritic cells toward silencing of cytotoxic immune responses. J Leukoc Biol. 2014;95(1):33-46.112. Svajger U, Tesic N, Rozman P. Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-gamma. Int Immunopharmacol. 2021;99:107978.113. Gocher-Demske AM, Cui J, Szymczak-Workman AL, et al. IFN-gamma-induction of Th1-like regulatory T cells controls antiviral responses. Nat Immunol. 2023;24(5):841-854.114. Meyaard L, Hovenkamp E, Otto SA, Miedema F. IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J Immunol. 1996;156(8):2776-2782.115. Sela U, Park CG, Park A, et al. Dendritic cells induce a subpopulation of IL-12Rbeta2-expressing Treg that specifically consumes IL-12 to control Th1 responses. PLoS One. 2016;11(1):e0146412.116. Ludewig B, Ochsenbein AF, Odermatt B, et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med. 2000;191(5):795-804.117. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90(7):2541-2548.118. Lanzar ZR, Aldridge DL, Jayaraman B, et al. De-coupling immune parameters and toxicity associated with IL-12 agonism. Cell Rep. 2025;44(6):115840.119. Liau LM, Ashkan K, Brem S, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with glioblastoma. JAMA Oncol. 2023;9(1):112-121.120. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257-e267.121. Boudewijns S, Westdorp H, Koornstra RH, et al. Immune-related adverse events of dendritic cell vaccination correlate with immunologic and clinical outcome in melanoma patients. J Immunother. 2016;39(6):241-248.122. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 2003;21(6):873-886.123. Nanjappa SG, Walent JH, Morre M, Suresh M. Effects of IL-7 on memory CD8 T cell homeostasis are influenced by the timing of therapy in mice. J Clin Invest. 2008;118(3):1027-1039.124. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-254.125. Ma S, Wang S, Ye Y, et al. Heterochronic parabiosis induces stem cell revitalization and systemic rejuvenation across aged tissues. Cell Stem Cell. 2022;29(6):990-1005.126. Montserrat-Vazquez S, Ali NJ, Gattazzo F, et al. Transplanting rejuvenated blood stem cells extends lifespan of aged immunocompromised mice. NPJ Regen Med. 2022;7(1):1.127. Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256.128. Oh HS, Rutledge J, Nachun D, et al. Organ aging signatures in the plasma proteome track health and disease. Nature. 2023;624(7990):164-172.129. Wang Y, Xiao S, Liu B, et al. Organ-specific proteomic aging clocks predict disease and longevity across diverse populations. Nat Aging. 2025;doi:10.1038/s43587-025-01016-8.130. Farr JN, Atkinson EJ, Achenbach SJ, et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women. Nat Med. 2024;30(9):2605-2612.131. Liu N, Wu J, Deng E, et al. Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results. Nat Med. 2025;doi:10.1038/s41591-025-03873-7.132. Finn OJ. Cancer immunology. N Engl J Med. 2008;358(25):2704-2715.133. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study. Lancet. 2000;356(9244):1795-1799.134. Fahy GM, Brooke RT, Watson JP, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019;18(6):e13028.135. Gross S, Erdmann M, Haendle I, et al. Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight. 2017;2(8):e91438.136. de Vries IJM, Bernsen MR, Lesterhuis WJ, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination. J Clin Oncol. 2005;23(24):5779-5787.137. Frischholz B, et al. Metabolic dormancy of long-lived memory T cells 26 years after vaccination. Nat Immunol. 2026;27(3):345-358.138. Manoharan MS, Lee GC, Harper N, et al. The 15-year survival advantage: immune resilience as a salutogenic force in healthy aging. Aging Cell. 2025;e70063.139. Zidar DA, Al-Kindi SG, Liu Y, et al. Association of lymphopenia with risk of mortality among adults in the US general population. JAMA Netw Open. 2019;2(12):e1916526.140. Wikby A, Ferguson F, Forsey R, et al. An immune risk phenotype, cognitive impairment, and survival in very late life. J Gerontol A Biol Sci Med Sci. 2005;60(5):556-565.141. Rankin LC, Artis D. Beyond host defense: emerging functions of the immune system in regulating complex tissue physiology. Cell. 2018;173(3):554-567.142. Poirier EZ. How stem cells respond to infection, inflammation and ageing. Nat Rev Immunol. 2025;doi:10.1038/s41577-025-01203-z.143. Manneken JD, Currie PD. Macrophage-stem cell crosstalk: regulation of the stem cell niche. Development. 2023;150(8):dev201510.144. Cheng QJ, Ohta S, Sheu KM, et al. NF-kappaB dynamics determine the stimulus specificity of epigenomic reprogramming in macrophages. Science. 2021;372(6548):1349-1353.145. Creemers S, Mclane LM, Sharkey MS, et al. A tipping point in cancer-immune dynamics predicts treatment response. J Immunother Cancer. 2021;9(8):e002913.146. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891-1901.147. Xia J, Tanaka Y, Koido S, et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol. 2003;170(4):1980-1986.148. Zhang Z, Su H, Fu S, et al. The immune cell atlas of longevity m

View quoted post on X

alphavestcapital.com Verified account @alphavestcap · Nov 30, 2025

@andrewcaravello
@alphavestcap. .
When you look at how modern immunotherapy actually works, $NWBO #DCVax is the only platform that addresses the full biology of solid tumors. Other approaches focus on one slice of the problem — stimulating NK cells, removing a checkpoint, inflaming a tissue, or adding a cytokine. DCVax is the only one that fixes the upstream failure that makes cancer invisible in the first place: the collapse of antigen recognition. And once you understand that, the IL-7 versus IL-15 question becomes central, because you cannot build durable tumor-specific immunity unless the underlying T-cell architecture is healthy. IL-7 does not behave the way you described, especially not in humans and especially not with RevImmune’s clinical-grade IL-7 (CYT107). The idea that IL-7 “expands everything” or behaves erratically mostly comes from engineered mouse models that do not reflect human immunology. In human trials — HIV, post-sepsis, post-chemotherapy, radiation injury, and bone-marrow failure — IL-7 reliably expands exactly the compartments the immune system needs to rebuild: naïve CD4, naïve CD8, central memory populations, and NK precursors. It improves T-cell receptor diversity, reduces exhaustion markers, preserves stem-like T cells, and repairs the immune architecture that chronic disease and cytotoxic therapy damage. And the safety signal is extremely consistent: IL-7 does all of this without autoimmune flares. If IL-7 were really expanding harmful clones, the NIH and NIAID trials would have shown it. They didn’t. RevImmune’s IL-7 (CYT107) is designed specifically for durable immune reconstruction. Their patents cover long-acting, controlled-release, and depot strategies that support sustained restoration — not short-lived inflation. That is why CYT107 is used in federally run immune-reconstitution programs: it behaves in humans as a stable, physiologic rebuilding signal. On durability: the only setting where IL-7 looks transient is in aged primates with nonfunctional thymus tissue, a model where nothing can regenerate. Humans — even older adults — retain measurable thymic output. And in modern IL-7 trials, CD4 and CD8 levels remain elevated for months to years because IL-7 expands both circulating populations and the progenitor pools that maintain them. Now compare that to IL-15. IL-15 produces a sharp, temporary burst of NK and CD8 activation and then falls off as those cells become less responsive to the signal. That exhaustion pattern appears with ALT-803, recombinant IL-15, and every IL-15 superagonist tested. IL-15 is stimulation, not reconstruction. It does not rebuild immune compartments. It does not support memory. It does not restore the architecture needed for long-term tumor control. And this matters when you talk about pairing a cytokine with DCVax. DCVax depends on a T-cell ecosystem that can form long-term, tumor-specific memory and tissue residency. That requires actual rebuilding, not a momentary surge. IL-7 is the cytokine that accomplishes that. IL-15 isn’t. That is why CYT107 is being tested in exactly the settings where durable immunity needs to be restored, not temporarily inflated. If IL-15 ever plays a role as a minor adjunct, DCVax’s combination patents already cover IL-15 in any form — recombinant, generic, or branded — but the biology rarely justifies using it because properly primed dendritic cells naturally provide localized IL-15 trans-presentation at the immune synapse. So here are the facts: IL-7 rebuilds the immune foundation. IL-15 produces a spike and fades. CYT107 is engineered for long-term reconstruction. DCVax requires durable, tumor-specific memory. IL-7 enables that. IL-15 doesn’t. This isn’t speculation. This is what human data show over and over again. And this is why DCVax stands alone — not as another stimulant, but as the platform that actually fixes recognition, rebuilding the only architecture that matters for long-term control of solid tumors.10:46 AM · Nov 30, 2025·Views183

View quoted post on X